Research programme: type IIb sodium-phosphate co-transporter inhibitors - Sanofi

Drug Profile

Research programme: type IIb sodium-phosphate co-transporter inhibitors - Sanofi

Alternative Names: NaP2 inhibitors; NaPi2b inhibitors; Npt2b inhibitors; RDX 002; SLC34A2 inhibitors

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ardelyx
  • Developer Sanofi
  • Class Small molecules
  • Mechanism of Action Type IIb sodium-phosphate cotransporter protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hyperphosphataemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hyperphosphataemia in USA
  • 01 Sep 2015 Sanofi decides to terminate its license for NaP2b phosphate inhibitor programme worldwide
  • 24 Feb 2014 Ardelyx licenses NaP2b phosphate inhibitor programme to Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top